Actuate Therapeutics Reports $4.87 Million Net Loss in Q2 2026, Seeks Additional Capital

Actuate Therapeutics, Inc. reported a net loss of $4.87 million for the second quarter of 2026, a decrease from a net loss of $5.95 million in the same period of the previous year. For the first half of 2026, the company recorded a net loss of $10.49 million, compared to $12.27 million for the first half of 2025. The reduction in losses is attributed to a decrease in total operating expenses, which fell to $4.91 million in Q2 2026 from $5.97 million in Q2 2025, and to $10.61 million for the first half of 2026, down from $12.33 million in the prior year. The company’s cash and cash equivalents decreased significantly to $4.43 million as of June 30, 2026, down from $13.16 million at the end of 2025.

The decline in operating expenses was primarily driven by reduced research and development costs, which decreased to $2.07 million in Q2 2026 from $2.76 million in Q2 2025. This reduction was largely due to lower external clinical study expenses associated with fewer patients enrolled in ongoing studies. General and administrative expenses also decreased to $2.84 million in Q2 2026 from $3.20 million in Q2 2025, reflecting lower personnel-related costs and other operational expenses. The company’s accumulated deficit increased to $165.10 million as of June 30, 2026, compared to $154.61 million at the end of 2025.

Actuate Therapeutics is focused on the development of elraglusib, a small molecule designed to inhibit glycogen synthase kinase-3 (GSK-3) for the treatment of various cancers. The company has made significant progress in its clinical studies, including a Phase 2 study of elraglusib in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (mPDAC), which demonstrated a statistically significant improvement in median overall survival. The company has also received FDA clearance to advance an oral formulation of elraglusib into a Phase 1/2 clinical study.

In terms of financing, Actuate Therapeutics has entered into an At Market Issuance Sales Agreement, allowing it to sell up to $100 million in common stock. During the first half of 2026, the company raised approximately $1.25 million through this facility. However, management has indicated that the current cash reserves may not be sufficient to meet operational needs beyond September 2026, highlighting the necessity for additional capital to support ongoing and future clinical development activities. The company continues to explore various financing options, including equity offerings and collaborations, to ensure its operational viability.